# China Montelukast API Market > China Montelukast API Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.47% - **2024:** $ 75.75 Million - **2025:** $ 84.44 Million - **2035:** $ 250 Million - **Key Players:** Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Cipla Limited (IN), Aurobindo Pharma (IN), Hikma Pharmaceuticals (GB), Sandoz (CH), Zydus Cadila (IN) **Report ID:** MRFR/HC/51337-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-montelukast-api-market-53098 --- ## Market Summary ## **China Montelukast API Market Overview:** As per MRFR analysis, the China Montelukast API Market Size was estimated at 67.5 (USD Million) in 2023. The China Montelukast API Market Industry is expected to grow from 90(USD Million) in 2024 to 250 (USD Million) by 2035. The China Montelukast API Market CAGR (growth rate) is expected to be around 9.733% during the forecast period (2025 - 2035). ### **Key China Montelukast API Market Trends Highlighted** Due to the rising incidence of respiratory diseases like asthma and allergic rhinitis in the general population, the China Montelukast API market is undergoing a number of noteworthy market trends. As China's healthcare programs concentrate on enhancing lung health, the demand for montelukast, which is frequently utilized for its anti-inflammatory qualities, has increased dramatically. The need for efficient therapies like Montelukast is further fueled by government programs that seek to enhance air quality and address pollution-related public health issues. This market offers opportunities, especially for improving the domestic production capacity of Montelukast APIs. In keeping with its goal of dominating the global pharmaceutical market, China is bolstering its pharmaceutical manufacturing industry, which presents a great opportunity for regional producers to increase output and make investments in research and development for novel formulations. Innovative distribution methods and products that address the unique requirements of the Chinese consumer may result from partnerships between academic institutions and industrial participants. There has been a recent trend toward stricter rules concerning API production procedures and quality requirements. Given China's evolving regulatory environment, adherence to safety and efficacy standards is of utmost importance.Furthermore, as more people look for online ways to buy their prescription drugs, the emergence of e-commerce platforms has increased patient access to Montelukast, propelling market expansion. These changes will cause the China Montelukast API market to change, offering chances as well as difficulties to those involved in the pharmaceutical sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **China Montelukast API Market Drivers** ### Rising Incidence of Allergic Diseases The growing prevalence of allergic disorders such as asthma, allergic rhinitis, and other respiratory conditions is a significant driver for the China Montelukast API Market Industry. According to data from the Chinese Center for Disease Control and Prevention (CDC), asthma prevalence in China has increased from 3.5% in 2010 to approximately 5.0% in 2020, affecting over 45 million individuals. This rise indicates a growing need for effective medications such as Montelukast, which is recognized for its efficacy in alleviating symptoms associated with allergic conditions.Major pharmaceutical companies operating in China, like Beijing Novartis Pharma Co., Ltd., are well-positioned to benefit from this increasing demand by providing innovative formulations of Montelukast, thereby driving market growth. ### Government Initiatives and Policies The Chinese government has been actively implementing healthcare reforms aimed at improving access to essential medications. The State Council of China launched a significant initiative to enhance the production and pricing of key therapeutic drugs, including Montelukast. This initiative has led to reduced costs and improved availability of the API to local manufacturers. The National Health Commission of China supports this effort by emphasizing the importance of affordability in pharmaceutical care.Enhanced government support is expected to positively impact the China Montelukast API Market Industry, encouraging increased local manufacturing and innovation in delivering these critical medications. ### Advancements in Manufacturing Technology Technological advancements in the production processes of pharmaceutical APIs have significantly impacted the China Montelukast API Market Industry. With the introduction of advanced techniques such as continuous manufacturing and process analytical technology, Chinese manufacturers are achieving higher efficiencies and reducing production costs. Reports from the Ministry of Industry and Information Technology indicate that investment in the pharmaceutical sector, including the production of APIs, has increased by 15% year-on-year, leading to enhanced capabilities for local producers.This progress positions China as a competitive player in the global market, ensuring a sustained growth trajectory for the Montelukast API segment. ## **China Montelukast API Market Segment Insights** ### **Montelukast API Market Application Insights** The Application segment of the China Montelukast API Market plays a crucial role in catering to various respiratory and allergic conditions that have become prevalent in the region. The landscape of this market has evolved due to the rising incidence of asthma and allergic disorders, which are significant public health concerns in China. With a growing urban population and increasing environmental pollution, the prevalence of asthma has surged, leading to a greater demand for effective treatments such as Montelukast. This segment serves as a critical component for patients managing their asthma, often resulting in improved quality of life and reduced healthcare costs associated with asthma exacerbations. Furthermore, allergic rhinitis also represents a substantial portion of this market, reflecting the need for effective management options in a climate where allergens are widely present. The rising awareness and diagnosis of allergic conditions have spurred demand for treatment options, creating opportunities for Montelukast to penetrate deeper into the market by addressing a wide spectrum of these conditions. Bronchospasm, another important application area, underscores the growing need for efficacious bronchodilators and anti-inflammatory medications in patient populations with chronic respiratory conditions. Urticaria, characterized by hives and itching, further emphasizes the diversity within the Application segment, showcasing Montelukast's versatility in providing relief for various allergic symptoms beyond respiratory conditions. Other conditions that fall within this segment also highlight the adaptability of Montelukast in the therapeutic landscape. Consequently, the growing understanding of the importance of effective treatment solutions for these conditions has established a promising growth trajectory for the China Montelukast API Market. As the market continues to advance, market growth will hinge on the increasing integration of Montelukast into treatment protocols for asthma, allergic rhinitis, and other related conditions. Strengthening healthcare infrastructure, enhancing patient education, and fostering research and development efforts in these areas will further underline the significance of the Application segment in addressing pressing health needs in China. Rising healthcare expenditure and emphasis on preventive measures only serve to underpin the expanding opportunities within the Application segment. This scenario positions the China Montelukast API Market not only as a vital contributor to the healthcare landscape but also as a significant driver of improvement in health outcomes for the population. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **China Montelukast API Market Key Players and Competitive Insights:** The China Montelukast API market is characterized by a highly competitive landscape where multiple players strive for market share and dominance. Montelukast, a widely used medication for managing asthma and allergic rhinitis, has seen increased demand due to the rise in respiratory disorders across the region. The competitive dynamics of this market involve not only the production capacities of the manufacturers but also their compliance with regulatory frameworks, technological advancements, and pricing strategies. As companies engage in research and development to create more efficient and cost-effective manufacturing processes, the market is becoming increasingly fragmented. The presence of both established firms and emerging players indicates a vibrant ecosystem ripe for innovation. Competition is often centered around product quality, cost efficiency, market access, and the ability to meet the needs of both domestic and international markets.Zhejiang Hisun Pharmaceutical has established a significant presence in the China Montelukast API market. The company's reputation is built on its ability to produce high-quality APIs that meet stringent regulatory requirements, making it a preferred partner for various pharmaceutical manufacturers. A key strength of Zhejiang Hisun Pharmaceutical lies in its robust research and development capabilities, which enable the company to innovate and improve production processes continually. The firm has invested heavily in modern technologies and facilities that enhance its production efficiency, allowing for competitive pricing and scalability. By focusing on quality and leveraging advanced manufacturing techniques, Zhejiang Hisun Pharmaceutical has secured a notable foothold in the market, positioning itself as a reliable supplier for both domestic needs and export opportunities. Guangdong Huanan Pharmaceutical has also carved a niche for itself in the China Montelukast API market, offering a range of key products that cater to the growing demand for respiratory therapeutic drugs. The company is recognized for its strategic initiatives, which include partnerships aiming at mutual growth through mergers and acquisitions, enabling it to expand its capabilities and market reach. With a strong focus on quality control and regulatory compliance, Guangdong Huanan Pharmaceutical has developed a reputation for delivering reliable and consistent products to its clients. The firm has enhanced its market presence by establishing collaborations with other pharmaceutical companies, thereby enhancing its distribution network. By investing in significant production infrastructure and navigating the evolving market dynamics, Guangdong Huanan Pharmaceutical continues to strengthen its position as a key player in the Montelukast API segment within China. ### **Key Companies in the China Montelukast API Market Include:** ## **China Montelukast API Market Industry Developments** In recent months, the China Montelukast API Market has seen notable developments. Zhejiang Hisun Pharmaceutical and Guangdong Huanan Pharmaceutical, along with other major players, are experiencing a growth phase attributed to increased demand for asthma and allergy medications. The Chinese pharmaceutical industry's expansion has resulted in increased valuations for companies like Nantong Jiangshan Pharmaceutical and Yichang Renfu Pharmaceutical, significantly impacting market dynamics. Notably, in September 2023, Hunan ErKang Pharmaceutical announced plans to enhance its manufacturing capabilities, indicating a focus on scaling production. Additionally, significant investments by Zhejiang Jiuzhou Pharmaceutical and Shaanxi Hanjiang Pharmaceutical highlight ongoing efforts to innovate and maintain competitive advantages in the market. There has been no publicly reported merger or acquisition activity involving the aforementioned companies in the Montelukast API sector recently. The market's growth is further supported by rising healthcare expenditures in China and the government's initiatives to boost domestic pharmaceutical manufacturing capabilities. In previous years, the increase in regulatory approvals also led to enhanced production and distribution channels, allowing companies like Hubei Wanbang Biopharmaceuticals and Sichuan Kelun Pharmaceutical to broaden their market reach significantly. ## **China Montelukast API Market Segmentation Insights** ### **Montelukast API Market Application****Outlook** ## Market Drivers ### Rising Healthcare Expenditure Healthcare expenditure in China has been on an upward trajectory, which positively impacts the montelukast api market. As the government allocates more resources to healthcare, the availability of treatments for chronic conditions like asthma is improving. In 2025, healthcare spending is projected to reach approximately 7.5% of GDP, reflecting a growing commitment to health services. This increase in expenditure is likely to enhance access to montelukast, as healthcare providers are better equipped to offer effective treatments. Moreover, the rising disposable income among the population allows for greater out-of-pocket spending on healthcare, further driving demand for montelukast. Consequently, The montelukast API market is poised for growth. This growth is due to healthcare investments translating into improved patient access and treatment options.. ### Expansion of Distribution Channels The montelukast API market is witnessing an expansion of distribution channels. This expansion is crucial for enhancing product availability across China.. With the rise of e-commerce and online pharmacies, patients now have easier access to montelukast, facilitating timely treatment for respiratory conditions. Traditional distribution methods are also evolving, with pharmacies and healthcare providers increasingly collaborating to ensure that montelukast is readily available. This diversification in distribution channels is likely to improve market penetration and reach, catering to a broader audience. As more patients gain access to montelukast through various platforms, the market is expected to experience significant growth. The expansion of distribution channels thus plays a pivotal role in shaping the future landscape of the montelukast api market. ### Growing Awareness of Preventive Healthcare There is a notable shift towards preventive healthcare in China, which is influencing the montelukast api market. As the population becomes more health-conscious, there is an increasing emphasis on managing chronic conditions before they escalate. Montelukast, known for its preventive capabilities in asthma management, aligns well with this trend. Educational campaigns and public health initiatives are raising awareness about the importance of early intervention and effective management of respiratory conditions. This growing awareness is likely to lead to increased prescriptions of montelukast, as healthcare providers advocate for its use in preventive care. The montelukast api market stands to benefit from this cultural shift towards proactive health management, potentially resulting in higher demand and market growth. ### Increasing Prevalence of Allergic Conditions The montelukast api market in China is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis. Reports indicate that approximately 30% of the population suffers from some form of allergy, leading to a heightened demand for effective treatments. Montelukast, as a leukotriene receptor antagonist, plays a crucial role in managing these conditions. The increasing awareness among healthcare professionals and patients about the benefits of montelukast is likely to drive market expansion. Furthermore, the Chinese government's initiatives to improve healthcare access and affordability may further enhance the market landscape, making montelukast a preferred choice for many patients. This trend suggests a robust future for the montelukast api market in China, as the healthcare system adapts to meet the needs of an allergy-prone population. ### Government Support for Pharmaceutical Development The montelukast API market is benefiting from substantial government support. This support is aimed at enhancing pharmaceutical development in China.. The government has implemented various policies to encourage research and development in the pharmaceutical sector, including financial incentives and streamlined approval processes. This support is particularly relevant for the production of montelukast, as it allows manufacturers to innovate and improve their production capabilities. Additionally, the Chinese government has set ambitious targets for increasing the domestic production of essential medicines, which includes montelukast. As a result, The montelukast API market is likely to see increased investment and growth. This growth is driven by favorable regulatory conditions and a commitment to improving public health outcomes.. ## Future Outlook The [Montelukast API Market](https://www.marketresearchfuture.com/reports/montelukast-api-market-7886) is projected to grow at 11.47% CAGR from 2025 to 2035, driven by increasing asthma prevalence and rising healthcare investments. **New opportunities:** - Expansion of online distribution channels for montelukast APIs. - Development of combination therapies to enhance market offerings. - Investment in R&D for novel formulations targeting pediatric patients. By 2035, the montelukast API market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing) In the China montelukast api market, the application segment demonstrates a dynamic distribution with asthma taking the lead in market share. This segment is predominantly driven by the high prevalence of asthma among the population, making it the largest contributor to the market. Conversely, allergic rhinitis is gaining attention as a rapidly growing segment, reflecting changing environmental factors and increasing awareness regarding allergy-related ailments. Growth trends indicate that while asthma remains a cornerstone of the market, allergic rhinitis is emerging as a critical area of focus. Factors such as urbanization, pollution, and lifestyle changes are propelling the demand for treatments in this segment. The rise in allergic conditions is also accompanied by increased healthcare spending and advancements in therapeutic options, making it a key area for market expansion. Asthma: Dominant vs. Allergic Rhinitis: Emerging Asthma stands out as the dominant application within the segment, characterized by its extensive patient base and established treatment protocols. The high incidence rate supports its leading position, attracting significant research and development investments. On the other hand, allergic rhinitis represents an emerging application, driven by a growing awareness of environmental allergies and the need for effective management solutions. This segment is becoming increasingly relevant as shifts in lifestyle and pollution levels elevate the prevalence of allergic conditions. Both segments reflect the evolving landscape of respiratory and allergy treatments, with asthma maintaining dominance while allergic rhinitis experiences rapid growth. ## Competitive Benchmarking The montelukast API market exhibits a dynamic competitive landscape characterized by a blend of established players and emerging competitors. Key growth drivers include increasing prevalence of asthma and allergic rhinitis, alongside a rising demand for cost-effective therapeutic options. Major companies such as Merck & Co (US), Teva Pharmaceutical Industries (IL), and Cipla Limited (IN) are strategically positioned to leverage their extensive research capabilities and established distribution networks. Merck & Co (US) focuses on innovation and product differentiation, while Teva Pharmaceutical Industries (IL) emphasizes cost leadership through efficient manufacturing processes. Cipla Limited (IN) is actively pursuing regional expansion, particularly in Asia, to enhance its market presence. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and operational efficiency.Key business tactics within the montelukast API market include localizing manufacturing and optimizing supply chains to reduce costs and improve responsiveness to market demands. The market structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for competitive pricing strategies, yet the influence of major companies remains significant, as they set industry standards and drive technological advancements. In October Merck & Co (US) announced a strategic partnership with a leading biotechnology firm to enhance its research capabilities in respiratory therapies. This collaboration is expected to accelerate the development of next-generation montelukast formulations, potentially positioning Merck as a leader in innovative asthma treatments. The strategic importance of this partnership lies in its potential to enhance Merck's product pipeline and strengthen its competitive edge in a rapidly evolving market. In September Teva Pharmaceutical Industries (IL) launched a new manufacturing facility in China, aimed at increasing its production capacity for montelukast API. This move is indicative of Teva's commitment to localizing its operations and reducing lead times for product delivery. The establishment of this facility not only enhances Teva's supply chain efficiency but also aligns with the growing demand for locally produced pharmaceuticals in the region. In August Cipla Limited (IN) expanded its distribution network in Southeast Asia, focusing on increasing access to montelukast API in emerging markets. This strategic expansion is crucial for Cipla as it seeks to capitalize on the rising demand for affordable asthma medications in these regions. By enhancing its distribution capabilities, Cipla is likely to strengthen its market position and drive revenue growth in the coming years. As of November current competitive trends in the montelukast API market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in manufacturing processes. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to foster innovation. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition towards a focus on technological advancements, supply chain reliability, and innovative product offerings. This shift underscores the importance of agility and responsiveness in meeting the changing needs of healthcare providers and patients. ## Recent News & Developments In recent months, the China Montelukast API Market has seen notable developments. Zhejiang Hisun Pharmaceutical and Guangdong Huanan Pharmaceutical, along with other major players, are experiencing a growth phase attributed to increased demand for asthma and allergy medications. The Chinese pharmaceutical industry's expansion has resulted in increased valuations for companies like Nantong Jiangshan Pharmaceutical and Yichang Renfu Pharmaceutical, significantly impacting market dynamics. Notably, in September 2023, Hunan ErKang Pharmaceutical announced plans to enhance its manufacturing capabilities, indicating a focus on scaling production. Additionally, significant investments by Zhejiang Jiuzhou Pharmaceutical and Shaanxi Hanjiang Pharmaceutical highlight ongoing efforts to innovate and maintain competitive advantages in the market. There has been no publicly reported merger or acquisition activity involving the aforementioned companies in the Montelukast API sector recently. The market's growth is further supported by rising healthcare expenditures in China and the government's initiatives to boost domestic pharmaceutical manufacturing capabilities. In previous years, the increase in regulatory approvals also led to enhanced production and distribution channels, allowing companies like Hubei Wanbang Biopharmaceuticals and Sichuan Kelun Pharmaceutical to broaden their market reach significantly. ## Report Scope | MARKET SIZE 2024 | 75.75(USD Million) | | --- | --- | | MARKET SIZE 2025 | 84.44(USD Million) | | MARKET SIZE 2035 | 250.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.47% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Cipla Limited (IN), Aurobindo Pharma (IN), Hikma Pharmaceuticals (GB), Sandoz (CH), Zydus Cadila (IN) | | Segments Covered | Application | | Key Market Opportunities | Growing demand for montelukast API driven by increasing respiratory disorders and regulatory support for generic formulations. | | Key Market Dynamics | Regulatory changes and competitive pressures shape the montelukast API market dynamics in China. | | Countries Covered | China | ## Frequently Asked Questions **Q: What was the market valuation of the China montelukast API market in 2024?** A: The market valuation was $75.75 Million in 2024. **Q: What is the projected market valuation for the China montelukast API market by 2035?** A: The projected market valuation for 2035 is $250.0 Million. **Q: What is the expected CAGR for the China montelukast API market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 11.47%. **Q: Which companies are considered key players in the China montelukast API market?** A: Key players include Merck & Co, Teva Pharmaceutical Industries, Mylan N.V., Cipla Limited, Aurobindo Pharma, Hikma Pharmaceuticals, Sandoz, and Zydus Cadila. **Q: What are the main application segments for montelukast API in China?** A: Main application segments include Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, and Others. **Q: What was the market size for the Asthma segment in 2024?** A: The market size for the Asthma segment was between $30.0 Million and $100.0 Million in 2024. **Q: How much revenue did the Allergic Rhinitis segment generate in 2024?** A: The Allergic Rhinitis segment generated revenue between $20.0 Million and $70.0 Million in 2024. **Q: What is the expected growth trend for the Bronchospasm segment in the coming years?** A: The Bronchospasm segment is projected to grow, with a market size between $10.0 Million and $30.0 Million in 2024. **Q: What is the potential market size for Urticaria in the China montelukast API market?** A: The potential market size for Urticaria ranges from $5.75 Million to $20.0 Million. **Q: How does the China montelukast API market compare to other regions?** A: While specific regional comparisons are not provided, the growth potential in China appears robust, with a projected valuation of $250.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-montelukast-api-market-53098*